

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on:



Date: June 30, 2003

By:

Susan L. Baka

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: REINER LAUS ET AL.

SERIAL NO.: 09/821,883

FILED: MARCH 30, 2001

FOR: COMPOSITIONS AND METHODS FOR
DENDRITIC CELL-BASED IMMUNOTHERAPY

EXAMINER: STEPHEN L. RAWLINGS

ART UNIT: 1641

CONFIRMATION NO.: 5347

JUL 08 2003
TECH CENTER 1600/2900

RECEIVED

13/A
KD
7-23-03

Amendment in Response to Notice to Comply

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Notice to Comply dated April 28, 2003, applicant respectfully requests entry of the following amendments.

In the specification:

On page 6, please replace the paragraph starting on line 6 with the following:

A
As used herein, "OVA" refers to native ovalbumin; "*" refers to the immunodominant OVA-derived peptide SIINFEKL (SEQ ID NO: 22); "HER500" refers to the recombinant fusion human HER-2 protein consisting of one half of its extracellular portion fused to the 1/4 of its intracellular part; "HER500*" refers to the recombinant fusion protein made of HER500 and the immunodominant OVA-derived peptide SIINFEKL (SEQ ID NO: 22) inserted between its extracellular and intracellular components; "HER500*•rGM-CSF" refers to the recombinant fusion protein composed of HER500* and rat granulocyte/macrophage colony-stimulating factor (GM-CSF); "HER500•hGM-CSF" refers to the recombinant fusion protein composed of HER500 and human GM-CSF; and "HER300*•rGM-CSF" refers to the recombinant fusion human HER-2 protein consisting of one half of its extracellular portion fused